IMNN
Imunon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.58
+1.28%Aug 11, 2026, 00:00 UTC
Imunon, Inc. reported a net loss of $2.8 million for Q2 2026, with a diluted loss per share of $0.54, and provided updates on its clinical studies including OVATION 2 and OVATION 3 trials for IMNN-001.
Source:Jun 23, 2026, 12:00 UTC
IMUNON announced that the independent Data Monitoring Committee recommended continuation of the Phase 3 OVATION 3 study without modification.
Source:Jun 16, 2026, 00:00 UTC
Imunon, Inc. elected Christine A. Pellizzari as a Class I director of its board of directors, effective June 16, 2026.
Jun 16, 2026, 00:00 UTC
Imunon, Inc. elected Frederick J. Fritz as a Class I director of its board of directors, effective June 16, 2026.
Jun 4, 2026, 00:00 UTC
Imunon, Inc. issued $7.72 million aggregate principal amount of secured promissory notes (8% A-1 Note and 5% B Note) due 2027, with proceeds for general corporate purposes.
Source: